Changing boundaries in the treatment of malignant gliomas.
Malignant gliomas are still among the most lethal and difficult tumors to treat; even the most intensive combinations of radio- and chemotherapy are not curative and yield only a modest impact on survival for most of these patients, as long-term survivors are less than 10%. There is a major need for new chemotherapeutic drugs and alternative therapeutic modalities. This review aims to define the best standard treatment in the common clinical practice and also summarizes the most promising lines of investigational research in the field of neuro-oncology, which will probably offer new and long-awaited valid therapy options for brain tumor patients.
Brandes
A A
AA
Divisione di Oncologia-Direzione Azienda Ospedale-Universita, Via Giustiniani 2, 35100 Padova, Italy. aabrandes@unipd.it
Basso
U
U
Pasetto
L M
LM
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000098:blood supply / Q000453:epidemiology / Q000628:therapy*; D003131:Combined Modality Therapy; D015316:Genetic Therapy; D005910:Glioma / Q000098:blood supply / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D011878:Radiotherapy; D013514:Surgical Procedures, Operative
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents